Suchergebnisse - "Dudnik, Elizabeth"

PubPharm (5)

1

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50

enthalten in: Clinical lung cancer | 2022

von Holtzman, L. | Moskovitz, M. | Urban, D. | +10

2

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50% : real-world data

enthalten in: Oncoimmunology | 2021

von Dudnik, E. | Moskovitz, M. | Rottenberg, Y. | +11

3

Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer

enthalten in: Immunotherapy | 2020

von Reinhorn, D. | Jacobi, O. | Icht, O. | +4

4

BRAF Mutant Lung Cancer : Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018

von Dudnik, E. | Peled, N. | Nechushtan, H. | +17

CommentIn: J Thorac Oncol. 2018 Aug;13(8):1055-1057. - PMID 30056857

5

RET Fusion Lung Carcinoma : Response to Therapy and Clinical Features in a Case Series of 14 Patients

enthalten in: Clinical lung cancer | 2017

von Sarfaty, M. | Moore, A. | Neiman, V. | +19

1
[1]